Novel platelet aggregation inhibitor for the treatment and prophylaxis of cardiovascular diseases
The aim of the portrayed invention is to develop and make new drugs for the primary- and secondary prophylaxis of thrombosis complications as well as the general treatment of cardiovascular diseases available, using inhibitors of the multidrug resistance protein (MRP) in human platelets, more specifically of MRP4.
Further Information: PDF
PVA Mecklenburg-Vorpommern AG
Phone: +49 (0)381/49 74 74 0
Contact
Antonio Martinez
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Superradiant atoms could push the boundaries of how precisely time can be measured
Superradiant atoms can help us measure time more precisely than ever. In a new study, researchers from the University of Copenhagen present a new method for measuring the time interval,…
Ion thermoelectric conversion devices for near room temperature
The electrode sheet of the thermoelectric device consists of ionic hydrogel, which is sandwiched between the electrodes to form, and the Prussian blue on the electrode undergoes a redox reaction…
Zap Energy achieves 37-million-degree temperatures in a compact device
New publication reports record electron temperatures for a small-scale, sheared-flow-stabilized Z-pinch fusion device. In the nine decades since humans first produced fusion reactions, only a few fusion technologies have demonstrated…
